CLGN - CIK 0001631487
The table below shows CollPlant Biotechnologies Ltd's cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$9.42M | -$14.09M | -$2.76M | -$13.70M | $2.50M | -$4.45M |
| Capital expenditure | $28.00K | $483.00K | $954.00K | $1.27M | $1.43M | $437.00K |
| Investing cash flow | -$27.00K | -$539.00K | -$1.16M | $28.92M | -$31.56M | -$519.00K |
| Dividends paid | - | - | - | - | - |
CollPlant Biotechnologies Ltd reported operating cash flow of -$9.42M for fiscal year 2025. That is up 33.2% from -$14.09M in fiscal 2024. Over the 8 fiscal years shown, operating cash flow declined from -$1.22M (FY 2018) to -$9.42M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $3.10M | $9.00K | $1.11M | $1.87M | $38.76M | $4.46M |